Monte Rosa Therapeutics I... (GLUE)
NASDAQ: GLUE
· Real-Time Price · USD
11.11
0.50 (4.71%)
At close: Oct 15, 2025, 3:59 PM
11.11
0.00%
After-hours: Oct 15, 2025, 07:32 PM EDT
Monte Rosa Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 75.62M | n/a | n/a | n/a |
Cost of Revenue | 8.12M | 6.22M | 8.56M | 2.13M |
Gross Profit | 67.5M | -6.22M | -8.56M | -2.13M |
Operating Income | -81.11M | -143.31M | -112.38M | -72.88M |
Interest Income | 10.57M | 9.33M | 3.76M | 46K |
Pretax Income | -70.13M | -135.01M | -108.5M | -73.96M |
Net Income | -72.7M | -135.35M | -108.5M | -73.96M |
Selling & General & Admin | 35.17M | 32.04M | 27.32M | 15.73M |
Research & Development | 121.56M | 105.05M | 85.06M | 57.16M |
Other Expenses | -8.12M | n/a | n/a | n/a |
Operating Expenses | 148.61M | 137.09M | 112.38M | 72.88M |
Interest Expense | n/a | n/a | 3.76M | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 156.73M | 143.31M | 112.38M | 72.88M |
Income Tax Expense | 2.57M | 338K | n/a | n/a |
Shares Outstanding (Basic) | 73.91M | 51.4M | 47.23M | 46.54M |
Shares Outstanding (Diluted) | 73.91M | 51.4M | 47.23M | 46.54M |
EPS (Basic) | -0.98 | -2.63 | -2.3 | -1.59 |
EPS (Diluted) | -0.98 | -2.63 | -2.3 | -1.59 |
EBITDA | -72.99M | -137.09M | -108.64M | -70.75M |
EBIT | -81.11M | -143.31M | -108.5M | -73.96M |
Depreciation & Amortization | 8.12M | 6.22M | 3.75M | 2.13M |
Source: Financial Modeling Prep. Financial Sources.